8-KRegulation FD

UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Sep 8, 2025)

Filed September 8, 2025For Securities:UNH

Summary

UnitedHealth Group Inc. (UNH) has filed an 8-K to disclose information regarding upcoming investor and analyst meetings scheduled between September 8-10, 2025. The primary purpose of these meetings is to reaffirm the company's previously issued adjusted 2025 earnings per share (EPS) expectations from July 29, 2025. This reaffirmation is noteworthy as it incorporates the closing of the Amedisys acquisition in August 2025. Management anticipates that this acquisition will be modestly dilutive to adjusted EPS in the near term, primarily due to financing costs and integration-related investments. The meetings may also involve discussions around UnitedHealth Group's overarching strategy, its competitive market positions, and a review of recent financial results, all consistent with prior disclosures. Investors should note that the information provided is for informational purposes and should not be considered a filing for Section 18 of the Exchange Act, unless expressly incorporated into a future filing.

Key Highlights

  • 1UNH will reaffirm its adjusted 2025 EPS guidance previously issued on July 29, 2025.
  • 2Investor and analyst meetings are scheduled from September 8-10, 2025.
  • 3The Amedisys acquisition closed in August 2025.
  • 4The Amedisys acquisition is expected to be modestly dilutive to adjusted EPS due to financing and integration costs.
  • 5Discussions in meetings may cover company strategy, market positions, and recent results.
  • 6Information provided in this 8-K is for disclosure purposes and not deemed 'filed' under Section 18 of the Securities Exchange Act.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce that UnitedHealth Group's senior leaders will be meeting with investors and analysts to reaffirm the company's adjusted 2025 earnings per share (EPS) expectations previously disclosed on July 29, 2025.

UnitedHealth Group expects the acquisition of Amedisys, which closed in August 2025, to be modestly dilutive to adjusted earnings per share. This dilution is attributed to the financing costs associated with the acquisition and the investments required for integration.

In addition to reaffirming EPS guidance, the meetings may include discussions on UnitedHealth Group's overall strategy, its current market positions, and a review of its recent financial performance, all consistent with information previously disclosed.

No, the information furnished in Item 7.01 (Regulation FD Disclosure) is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into any other filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, unless specifically stated otherwise in a future filing.